No Data
No Data
We Think Yifeng Pharmacy Chain (SHSE:603939) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Yifeng Pharmacy Chain (SHSE:603939) Sheds 4.7% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And while active stock picking involves risks (and requires diver
Yifeng Pharmacy (603939.SH) plans to pay 0.5 yuan per share to 0.2 shares in 2023, excluding interest on June 7
Yifeng Pharmacy (603939.SH) announced that the company plans to distribute a cash dividend of 0.50 yuan per share in 2023...
Investors Still Waiting For A Pull Back In Yifeng Pharmacy Chain Co., Ltd. (SHSE:603939)
With a median price-to-earnings (or "P/E") ratio of close to 32x in China, you could be forgiven for feeling indifferent about Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) P/E ratio of 31.6x. Whi
Yifeng Pharmacy Chain's (SHSE:603939) Solid Earnings Are Supported By Other Strong Factors
Even though Yifeng Pharmacy Chain Co., Ltd.'s (SHSE:603939) recent earnings release was robust, the market didn't seem to notice. Investors are probably missing some underlying factors which are enco
Yifeng Pharmacy (603939.SH) announced its 2023 annual results, with net profit of 1,412 billion yuan, an increase of 11.9% year-on-year
Yifeng Pharmacy (603939.SH) released the 2023 annual performance report. The company achieved operating income of 2 during the reporting period...
No Data